Skip to main content

UPDATE 1-Biogen scraps development of therapy for rare brain disease

Biogen Inc said on Friday it would discontinue development of its experimental therapy for a rare brain disease after the treatment failed a mid-stage trial.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.